相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
1445379-92-9
- 规格:
10 mM * 1 mL/1 mg/5 mg/10 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥4846.0 |
|---|---|---|---|
| 规格: | 1 mg | 产品价格: | ¥1500.0 |
| 规格: | 5 mg | 产品价格: | ¥3500.0 |
| 规格: | 10 mg | 产品价格: | ¥5000.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
ALS-8112
CAS No. : 1445379-92-9
MCE 国际站:ALS-8112
产品活性:ALS-8112是高效,选择性的呼吸道合胞病毒(RSV)聚合酶抑制剂。5'-三磷酸形式的ALS-8112抑制RSV聚合酶,IC50值为0.02 μM。
研究领域:Anti-infection
作用靶点:RSV
In Vitro: The 5'-triphosphate form of ALS-8112 (ALS-8112-TP) is the active form of the drug and selectively inhibits RSV polymerase through chain termination of RNA synthesis. ALS-008112 enters various types of epithelial cells in the respiratory tract and is subsequently phosphorylated to form an intracellular nucleoside triphosphate with a half-life of approximately 29 hours. The nucleoside triphosphate analogue inhibits RSV replication by means of chain termination. ALS-8112 is a pan-strain inhibitor of RSV replication in vitro. The RNA transcription activity of the RSV–RNP complex is dose-proportionally inhibited by ALS-8112-TP with an IC50 of 0.020 ± 0.008 μM.
相关产品:Bioactive Compound Library Plus | Ribavirin | Roflumilast | Ac-CoA Synthase Inhibitor1 | GS-443902 trisodium | Amentoflavone | Ziresovir | PC786 | Rilematovir | Presatovir | Rostafuroxin | Sisunatovir | Palivizumab | EIDD-2749 | TMC353121 | Motavizumab | Lumicitabine | RSV604 | Mindeudesivir hydrobromide | AVG-233 | Nirsevimab | Clesrovimab | Enzaplatovir | Suptavumab | 4-Methoxycinnamaldehyde | (S)-Enzaplatovir | Zelicapavir | BMS-433771 | RSV-IN-1
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料

















